CDXI
Cardax, Inc. [CDXI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CDXI Stock Summary
In the News
CDXI Financial details
Company Rating
Neutral
Market Cap
800
Income
0
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
17 May 2024
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
0.11
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-513%
ROE
84%
ROC
0.34%
Gross Margin
64%
Oper. Margin
-568%
Profit Margin
-1357%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.0E-4-0.43
52W High
-
52W Low
-
RSI
-
Rel Volume
-
Avg Volume
12
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.027
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
CDXI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.37 | 1.05 | 0.72 | 0 | 0 | |
| Net income per share | -6.32 | -8.4 | -9.82 | 0 | 0 | |
| Operating cash flow per share | -5.03 | -5.18 | -2.41 | 0 | 0 | |
| Free cash flow per share | -5.09 | -5.27 | -2.43 | 0 | 0 | |
| Cash per share | 0.38 | 0.03 | 0.03 | 0 | 0 | |
| Book value per share | -5.55 | -10.58 | -13.7 | 0 | 0 | |
| Tangible book value per share | -6.24 | -11.2 | -14.1 | 0 | 0 | |
| Share holders equity per share | -5.55 | -10.58 | -13.7 | 0 | 0 | |
| Interest debt per share | 0.01 | 4.74 | 9.63 | 0 | 0 | |
| Market cap | 25.46M | 6.9M | 1.27M | 0 | 0 | |
| Enterprise value | 25.22M | 9.48M | 6.03M | 0 | 0 | |
| P/E ratio | -6.33 | -1.21 | -0.17 | 0 | 0 | |
| Price to sales ratio | 16.85 | 9.71 | 2.35 | 0 | 0 | |
| POCF ratio | -7.96 | -1.96 | -0.71 | 0 | 0 | |
| PFCF ratio | -7.87 | -1.93 | -0.7 | 0 | 0 | |
| P/B Ratio | -7.2 | -0.96 | -0.12 | 0 | 0 | |
| PTB ratio | -7.2 | -0.96 | -0.12 | 0 | 0 | |
| EV to sales | 16.69 | 13.34 | 11.19 | 0 | 0 | |
| Enterprise value over EBITDA | -6.32 | -2.35 | -1.91 | 0 | 0 | |
| EV to operating cash flow | -7.88 | -2.69 | -3.37 | 0 | 0 | |
| EV to free cash flow | -7.79 | -2.65 | -3.34 | 0 | 0 | |
| Earnings yield | -0.16 | -0.83 | -5.78 | 0 | 0 | |
| Free cash flow yield | -0.13 | -0.52 | -1.43 | 0 | 0 | |
| Debt to equity | 0 | -0.36 | -0.47 | 0 | 0 | |
| Debt to assets | 0 | 1.29 | 3.36 | 0 | 0 | |
| Net debt to EBITDA | 0.06 | -0.64 | -1.51 | 0 | 0 | |
| Current ratio | 0.34 | 0.2 | 0.11 | 0 | 0 | |
| Interest coverage | -951.62 | -6.54 | -1.28 | 0 | 0 | |
| Income quality | 0.8 | 0.69 | 0.35 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3 | 5.75 | 6 | 0 | 0 | |
| Research and developement to revenue | 0.18 | 0.44 | 0.25 | 0 | 0 | |
| Intangibles to total assets | 0.18 | 0.21 | 0.21 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.02 | 0.01 | 0 | 0 | |
| Capex to revenue | -0.02 | -0.09 | -0.03 | 0 | 0 | |
| Capex to depreciation | -1.2 | -1.56 | -0.42 | 0 | 0 | |
| Stock based compensation to revenue | 0.43 | 1 | 1.17 | 0 | 0 | |
| Graham number | 28.11 | 44.74 | 55.01 | 0 | 0 | |
| ROIC | 1.14 | 1 | 0.82 | 0 | 0 | |
| Return on tangible assets | -1.99 | -3.58 | -6.51 | 0 | 0 | |
| Graham Net | -7.69 | -12.43 | -14.92 | 0 | 0 | |
| Working capital | -3.88M | -6.55M | -9.43M | 0 | 0 | |
| Tangible asset value | -3.97M | -7.62M | -10.5M | 0 | 0 | |
| Net current asset value | -3.97M | -7.63M | -10.5M | 0 | 0 | |
| Invested capital | 0 | -0.36 | -0.47 | 0 | 0 | |
| Average receivables | 97.16K | 181.43K | 102.88K | 0 | 0 | |
| Average payables | 1.3M | 1.77M | 1.62M | 844.68K | 0 | |
| Average inventory | 910.4K | 1.33M | 1.09M | 497.16K | 0 | |
| Days sales outstanding | 37.95 | 105.64 | 0 | 0 | 0 | |
| Days payables outstanding | 1.04K | 1.63K | 3.14K | 0 | 0 | |
| Days of inventory on hand | 772.08 | 1.24K | 1.85K | 0 | 0 | |
| Receivables turnover | 9.62 | 3.46 | 0 | 0 | 0 | |
| Payables turnover | 0.35 | 0.22 | 0.12 | 0 | 0 | |
| Inventory turnover | 0.47 | 0.29 | 0.2 | 0 | 0 | |
| ROE | 1.14 | 0.79 | 0.72 | 0 | 0 | |
| Capex per share | -0.06 | -0.09 | -0.02 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value | 0 | 0 | 0 | 0 | 0 | |
| P/E ratio | 0 | 0 | 0 | 0 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 0 | 0 | 0 | 0 | 0 | |
| PTB ratio | 0 | 0 | 0 | 0 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0 | 0 | 0 | 0 | 0 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0 | 0 | 0 | 0 | 0 | |
| Current ratio | 0 | 0 | 0 | 0 | 0 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 0 | 0 | 0 | 0 | |
| ROIC | 0 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | 0 | 0 | 0 | 0 | 0 | |
| Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
| Net current asset value | 0 | 0 | 0 | 0 | 0 | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0 | 0 | 0 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
CDXI Frequently Asked Questions
What is Cardax, Inc. stock symbol ?
Cardax, Inc. is a US stock , located in Honolulu of Hi and trading under the symbol CDXI
What is Cardax, Inc. stock quote today ?
Cardax, Inc. stock price is $- today.
Is Cardax, Inc. stock public?
Yes, Cardax, Inc. is a publicly traded company.
Company Profile
- Volume Average 12
- Market Capitalization 800
- Employee 10
- CEO Mr. David G. Watumull
- Headquarters Honolulu,HI,US
- IPO Date 2013-03-06
-
Website
https://www.cardaxpharma.com 
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.
